There is statistically significant evidence that the carrier status of NOS2 SNVs rs944725, rs2779252, and rs8072199 was associated with a risk of meningioma (p = 0.03), SNV rs4795067 was associated with a risk of glioblastoma (p = 0.05) and meningioma (p = 0.02), while SNV rs2297516 (p = 0.05) was associated with a risk of glioma [30]. This evidence concerns the gene NOS2 and central nervous system cancer.